Pharmaceuticals Sector: Comprehensive Industry Analysis (Q2/H1 Fy26)

This report synthesizes data from multiple investor documents and concall transcripts for Q2 and H1 FY26, providing an exhaustive, in-depth analysis of the Pharmaceuticals sector. It covers market dynamics, financial performance, competitive landscapes, operational characteristics, growth drivers, risks, capital allocation strategies, and future outlook, complemented by detailed company profiles and comparative insights.

---

A. Industry Overview & Market Landscape

The Pharmaceuticals sector, as evidenced by the Q2 and H1 FY26 performance of key Indian players, presents a dynamic and multi-faceted landscape characterized by robust domestic growth, strategic global expansion, increasing focus on complex and differentiated products, and significant investments in advanced manufacturing and R&D capabilities. The industry is navigating a complex environment of evolving regulatory standards, intense generic competition, and emerging therapeutic opportunities, particularly in chronic care, biosimilars, and novel modalities like GLP-1s, ADCs, and cell/gene therapies.

Total Addressable Market Size And Growth Rates

While specific aggregate market sizes for the entire sector are not explicitly provided, individual company performances and segment-specific data offer insights into the underlying growth drivers. The Indian Pharmaceutical Market (IPM) is a significant growth engine, with Cipla reporting an overall market growth of 8% for its branded prescriptions business (IQVIA MAT September '25) and Dr. Reddy's noting IPM growth at 7.8%. RPG Life Sciences, with its domestic formulation business growing at 17.2% in Q2 FY26 (2.2x market growth of 7.7%), further underscores the healthy expansion within India. Torrent Pharmaceuticals' India revenue grew by 12% in Q2 FY26 and 11% in H1 FY26, indicating a strong domestic market.

Globally, the market for specific high-value segments is projected for substantial growth. The Peptide API market, for instance, is poised to reach $14 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 18.5%, a key focus area for Neuland Laboratories. The emerging GLP-1 market, while nascent for many Indian players, represents a significant future opportunity, with companies like Cipla, Dr. Reddy's, Gland Pharma, and Gufic Biosciences actively positioning themselves for it.

Market Structure And Segmentation

The sector is highly segmented, reflecting diverse business models and product portfolios:

1. Branded Formulations (India): This segment remains a cornerstone for many companies, driven by chronic therapies. Cipla's "One-India" business, with 61.8% chronic mix, saw 7% Y-o-Y growth, with key therapies like Anti-diabetes (10%), Cardiac (13%), Urology (17%), and Dermatology (18%) outperforming. Dr. Reddy's India business grew 13% Y-o-Y, reaching 9th position in IPM. Torrent Pharma's India revenue grew 12% in Q2 FY26. RPG Life Sciences' domestic formulations grew 17.2%, significantly outpacing the market. Sanofi India, despite overall moderate domestic growth of 3% YTD Sept/25, focuses on its Diabetes franchise (48% of domestic sales) and partnerships for legacy brands. Zota Healthcare's Davaindia chain focuses on affordable private-label generics, with 60% of revenue from chronic diseases.
2. Generic Formulations (International): The U.S. market, while offering scale, is characterized by intense competition and price erosion. Dr. Reddy's North America generics revenue declined 16% Y-o-Y in Q2 FY26, primarily due to Lenalidomide and competition in other products. Cipla, however, maintains a strong position in specific niches, being the #1 player in the U.S. albuterol MDI market with 22% share. Gland Pharma's U.S. revenue grew 8% Y-o-Y, driven by new launches and RTU products, demonstrating success in complex injectables. Torrent Pharma's U.S. revenue grew 26% in Q2 FY26. NATCO Pharma heavily relies on export formulations (78.4% of Q2 FY26 revenue) and has a robust pipeline of Para IV filings.
3. Active Pharmaceutical Ingredients (APIs): This segment serves both captive consumption and third-party sales. Neuland Laboratories' Generic Drug Substances (GDS) business, particularly Specialty, is a key focus. Laurus Labs' API business, especially ARVs, contributes significantly. Dr. Reddy's PSAI business grew 8% Y-o-Y. RPG Life Sciences' API business was impacted by a fire incident but is expected to recover. Morepen Laboratories' API business (66% of pharma business) is diversified across continents. Acutaas Chemicals focuses on Advanced Pharmaceutical Intermediates.
4. Contract Development and Manufacturing Organization (CDMO): This high-growth, high-margin segment is a strategic priority for several companies. Laurus Labs' CDMO business saw healthy growth of 88% in H1 FY26, driven by mid-to-late phase programs and new assets. Gland Pharma is building itself as a "high-end inno